Yulia L. Skorodok
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yulia L. Skorodok has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
- Elena V. Plotnikova
Saint-Petersburg State Pediatric Medical University
7 shared publications - Irina Yu. Ioffe
Saint-Petersburg State Pediatric Medical University
5 shared publications - A. V. Kozhevnikova
Saint-Petersburg State Pediatric Medical University
4 shared publications - Irena I. Nagornaya
Saint-Petersburg State Pediatric Medical University
4 shared publications - Lyudmila Aleksandrovna Zhelenina
Санкт-Петербургский государственный педиатрический медицинский университет
4 shared publications - Elena B. Bashnina
North-Western State Medical University Named After I.I. Mechnikov
3 shared publications
Latest Publications
- Open Access
- 11 September 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 11,p. 271-277
Family case of Morris syndrome associated with a novel variant in the androgen receptor gene
Androgen insensitivity syndrome (AIS) is one of the most common causes of disorders of sex development (DSD) with a 46,XY karyotype, caused by pathogenic variants in the androgen receptor gene (AR) leading to complete or partial loss of tissue sensitivity. No specific clinical or laboratory criteria exist for differential diagnosis from other forms of DSD, and diagnosis verification is often complicated by insufficient evidence to assess the pathogenicity of the identified variant. This article is of interest as it describes a familial case of Morris syndrome in two siblings with a 46,XY karyotype, caused by a previously unreported variant c.2342T>C in the AR gene (p.Met781Thr). Both probands had a female phenotype and uterine and vaginal aplasia; DSD was suspected during surgical repair of inguinal hernias, in the sacs of which testicular tissue was found. The diagnosis was confirmed by molecular genetic testing. Laparoscopic gonadectomy was performed, estradiol hormone replacement therapy was initiated, and vitamin D and calcium supplements were prescribed due to osteoporosis. The familial nature of the case allowed the previously unreported AR gene variant to be classified as pathogenic and causative. Thus, an inguinal hernia in a phenotypic girl requires mandatory exclusion of DSD, first of all Morris syndrome, through karyotyping and molecular genetic testing.
- 11 September 2026
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 11,p. 271-277
Open AccessFamily case of Morris syndrome associated with a novel variant in the androgen receptor gene
Androgen insensitivity syndrome (AIS) is one of the most common causes of disorders of sex development (DSD) with a 46,XY karyotype, caused by pathogenic variants in the androgen receptor gene (AR) leading to complete or partial loss of tissue sensitivity. No specific clinical or laboratory criteria exist for differential diagnosis from other forms of DSD, and diagnosis verification is often complicated by insufficient evidence to assess the pathogenicity of the identified variant. This article is of interest as it describes a familial case of Morris syndrome in two siblings with a 46,XY karyotype, caused by a previously unreported variant c.2342T>C in the AR gene (p.Met781Thr). Both probands had a female phenotype and uterine and vaginal aplasia; DSD was suspected during surgical repair of inguinal hernias, in the sacs of which testicular tissue was found. The diagnosis was confirmed by molecular genetic testing. Laparoscopic gonadectomy was performed, estradiol hormone replacement therapy was initiated, and vitamin D and calcium supplements were prescribed due to osteoporosis. The familial nature of the case allowed the previously unreported AR gene variant to be classified as pathogenic and causative. Thus, an inguinal hernia in a phenotypic girl requires mandatory exclusion of DSD, first of all Morris syndrome, through karyotyping and molecular genetic testing.
- Open Access
- 22 July 2026
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 72 (3) , 80-85
Microcephalic osteodysplastic primary dwarfism type II with hypergonadotropic hypogonadism in a 16-year-old patient
Microcephalic osteodysplastic primary dwarfism type II (MOPDII) is a form of primordial nanism characterized by extreme short stature, microcephaly, specific phenotype, maxillofacial dysmorphisms, skeletal dysplasia, disorders of carbohydrate metabolism, and neurovascular abnormalities. This article describes a patient with a Seckel syndrome phenotype presenting with left internal carotid artery aneurysms with intracerebral hemorrhages, thrombocytosis, arterial hypertension, and diabetes mellitus due to insulin resistance confirmed by a low Matsuda index. Target carbohydrate metabolism values were achieved on metformin therapy. Clinical exome sequencing revealed two rare heterozygous variants in the PCNT gene: c.6220C>T (p.Gln2074*) and c.4564-12T>A. Comparison of the results of the molecular genetic study and the patient’s phenotype allowed us to verify the diagnosis of MOPDII. Hypergonadotropic hypogonadism was described for the first time in this syndrome.
- 22 July 2026
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 72 (3) , 80-85
Open AccessMicrocephalic osteodysplastic primary dwarfism type II with hypergonadotropic hypogonadism in a 16-year-old patient
Microcephalic osteodysplastic primary dwarfism type II (MOPDII) is a form of primordial nanism characterized by extreme short stature, microcephaly, specific phenotype, maxillofacial dysmorphisms, skeletal dysplasia, disorders of carbohydrate metabolism, and neurovascular abnormalities. This article describes a patient with a Seckel syndrome phenotype presenting with left internal carotid artery aneurysms with intracerebral hemorrhages, thrombocytosis, arterial hypertension, and diabetes mellitus due to insulin resistance confirmed by a low Matsuda index. Target carbohydrate metabolism values were achieved on metformin therapy. Clinical exome sequencing revealed two rare heterozygous variants in the PCNT gene: c.6220C>T (p.Gln2074*) and c.4564-12T>A. Comparison of the results of the molecular genetic study and the patient’s phenotype allowed us to verify the diagnosis of MOPDII. Hypergonadotropic hypogonadism was described for the first time in this syndrome.
- Open Access
- 29 June 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
Open-Label 9-Year Follow-Up Extension Phase 2 Study of Once-Weekly Somatrogon in Children With Growth Hormone Deficiency
Context: : Growth hormone deficiency (GHD) can lead to significant growth and developmental issues, necessitating long-term treatment. Once-weekly somatrogon is a long-acting recombinant human growth hormone analogue, approved for treatment of children with GHD. Objective: : Assess the long-term safety and efficacy of somatrogon in children with GHD. Design: : Open-label extension (OLE) study following an initial 12-month open-label phase 2 study. Setting: : Conducted at 14 centers across Hungary, Bulgaria, Belarus, Ukraine, Russia, Greece, and the US. Patients or Other Participants: : Fifty-three children with GHD (67.9% male, mean age 6.0±2.1 years) completed the phase 2 study and 48 entered the OLE. Intervention(s): : Participants received once-weekly somatrogon for up to 9 years. Main Outcome Measure(s): : Safety endpoints included adverse events (AEs), antidrug antibodies (ADAs), local site injection reactions, and insulin-like growth factor-I SDS. Efficacy endpoints included annual height velocity (HV), change in height SDS, and annual bone maturation. Results: Treatment-emergent AEs (TEAEs) incidence was 52.1% at OLE year (Y) 1, decreasing to 23.8% by Y9. Serious AEs were rare with only isolated cases reported. ADA positivity was observed, but no neutralizing antibodies were found. No correlation between ADA presence and TEAE incidence or severity was noted, nor was there a difference in growth based on ADA presence. Mean annualized HV remained > 5 cm/year, and height SDS improved from -4.0 at baseline to -0.2 by Y8. No changes in the ratio of bone age/chronological age were observed. Conclusions: Once-weekly somatrogon is a well-tolerated and a viable long-term treatment for GHD in children. More real-world data are needed. Clinicaltrials.gov: NCT01592500.
- 29 June 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
Open AccessOpen-Label 9-Year Follow-Up Extension Phase 2 Study of Once-Weekly Somatrogon in Children With Growth Hormone Deficiency
Context: : Growth hormone deficiency (GHD) can lead to significant growth and developmental issues, necessitating long-term treatment. Once-weekly somatrogon is a long-acting recombinant human growth hormone analogue, approved for treatment of children with GHD. Objective: : Assess the long-term safety and efficacy of somatrogon in children with GHD. Design: : Open-label extension (OLE) study following an initial 12-month open-label phase 2 study. Setting: : Conducted at 14 centers across Hungary, Bulgaria, Belarus, Ukraine, Russia, Greece, and the US. Patients or Other Participants: : Fifty-three children with GHD (67.9% male, mean age 6.0±2.1 years) completed the phase 2 study and 48 entered the OLE. Intervention(s): : Participants received once-weekly somatrogon for up to 9 years. Main Outcome Measure(s): : Safety endpoints included adverse events (AEs), antidrug antibodies (ADAs), local site injection reactions, and insulin-like growth factor-I SDS. Efficacy endpoints included annual height velocity (HV), change in height SDS, and annual bone maturation. Results: Treatment-emergent AEs (TEAEs) incidence was 52.1% at OLE year (Y) 1, decreasing to 23.8% by Y9. Serious AEs were rare with only isolated cases reported. ADA positivity was observed, but no neutralizing antibodies were found. No correlation between ADA presence and TEAE incidence or severity was noted, nor was there a difference in growth based on ADA presence. Mean annualized HV remained > 5 cm/year, and height SDS improved from -4.0 at baseline to -0.2 by Y8. No changes in the ratio of bone age/chronological age were observed. Conclusions: Once-weekly somatrogon is a well-tolerated and a viable long-term treatment for GHD in children. More real-world data are needed. Clinicaltrials.gov: NCT01592500.
- Open Access
- 14 September 2025
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 71 (4) , 71-76
Cushing’s disease in a 15-year-old boy, manifesting in prepubertal age
Cushing’s disease (CD) is the leading form (75–80%) of the endogenous hypercortisolism (EH) in adolescents. Despite the obvious clinical manifestations, the diagnosis of CD is complicated because of the need of several research methods, the risk of false-positive and false-negative results, difficulties in interpretation and the low percentage of MR-imaging in children. The present patient had noted excessive weight gain since the age of 10 years, a decrease in growth rate was detected retrospectively, absolute short stature developed by the age of 14.5 years. An examination at the age of 15 revealed an inversion of the circadian cortisol rhythm (9:00 378.4 nmol/l, 23:00 598.9 nmol/l), an increase in the cortisol level in saliva at 23:00 (20.32 nmol/l) and excretion in urine (981.5 mcg/day). The overnight dexamethasone test (ODT) was positive (cortisol 44.26 nmol/l), ACTH was in the “gray zone” (22.19 pg/ml). MRI with contrast showed signs of a heterogeneous pituitary gland structure. When patient was re-examined at 15.5 years the inversion of the circadian rhythm of cortisol was accompanied by absolute hypercortisolemia (9:00 843.4 nmol/l, 23:00 929.4 nmol/l), ODT became negative (cortisol 235 nmol/l), ACTH level remained in the “gray zone” (25.1 pg/ml). MRI with contrast showed pituitary adenoma 6×4 mm. An ACTH level gradient between the left inferior petrosal sinus and peripheral blood of 13.3 confirmed CD. After transsphenoidal adenomectomy, a cortisol level of 39.4 nmol/l indicated remission with a low risk of relapse; subsequently a reverse development of EH symptoms were noted. Postoperative diabetes insipidus and primary hypothyroidism required replacement therapy.
- 14 September 2025
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 71 (4) , 71-76
Open AccessCushing’s disease in a 15-year-old boy, manifesting in prepubertal age
Cushing’s disease (CD) is the leading form (75–80%) of the endogenous hypercortisolism (EH) in adolescents. Despite the obvious clinical manifestations, the diagnosis of CD is complicated because of the need of several research methods, the risk of false-positive and false-negative results, difficulties in interpretation and the low percentage of MR-imaging in children. The present patient had noted excessive weight gain since the age of 10 years, a decrease in growth rate was detected retrospectively, absolute short stature developed by the age of 14.5 years. An examination at the age of 15 revealed an inversion of the circadian cortisol rhythm (9:00 378.4 nmol/l, 23:00 598.9 nmol/l), an increase in the cortisol level in saliva at 23:00 (20.32 nmol/l) and excretion in urine (981.5 mcg/day). The overnight dexamethasone test (ODT) was positive (cortisol 44.26 nmol/l), ACTH was in the “gray zone” (22.19 pg/ml). MRI with contrast showed signs of a heterogeneous pituitary gland structure. When patient was re-examined at 15.5 years the inversion of the circadian rhythm of cortisol was accompanied by absolute hypercortisolemia (9:00 843.4 nmol/l, 23:00 929.4 nmol/l), ODT became negative (cortisol 235 nmol/l), ACTH level remained in the “gray zone” (25.1 pg/ml). MRI with contrast showed pituitary adenoma 6×4 mm. An ACTH level gradient between the left inferior petrosal sinus and peripheral blood of 13.3 confirmed CD. After transsphenoidal adenomectomy, a cortisol level of 39.4 nmol/l indicated remission with a low risk of relapse; subsequently a reverse development of EH symptoms were noted. Postoperative diabetes insipidus and primary hypothyroidism required replacement therapy.
- Open Access
- 22 July 2025
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 71 (3) , 62-67
A case of thyroid hormone resistance syndrome due to previously undescribed mutation in the THRA gene
Thyroid hormone resistance (THR) syndrome is characterized by decreased sensitivity of peripheral tissues to active forms of thyroid hormones. We present a clinical case of a patient, demonstrating symptoms of hypothyroidism while having subnormal FT4 and normal TSH and total T3 levels. Massive parallel sequencing allowed us to identify a previously undescribed heterozygous THRA c.1198C>G (p.Leu400Val) variant that arose de novo. The results of genetic testing corresponded well with the patient’s phenotype that made it possible to verify the diagnosis of THR. Levothyroxine replacement therapy did not resulted in a significant clinical improvement; the use of supraphysiological doses led to refinement of the lipid profile but was accompanied by the appearance of some symptoms of thyrotoxicosis.
- 22 July 2025
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 71 (3) , 62-67
Open AccessA case of thyroid hormone resistance syndrome due to previously undescribed mutation in the THRA gene
Thyroid hormone resistance (THR) syndrome is characterized by decreased sensitivity of peripheral tissues to active forms of thyroid hormones. We present a clinical case of a patient, demonstrating symptoms of hypothyroidism while having subnormal FT4 and normal TSH and total T3 levels. Massive parallel sequencing allowed us to identify a previously undescribed heterozygous THRA c.1198C>G (p.Leu400Val) variant that arose de novo. The results of genetic testing corresponded well with the patient’s phenotype that made it possible to verify the diagnosis of THR. Levothyroxine replacement therapy did not resulted in a significant clinical improvement; the use of supraphysiological doses led to refinement of the lipid profile but was accompanied by the appearance of some symptoms of thyrotoxicosis.
- Open Access
- 22 July 2025
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 71 (3) , 51-55
Two cases of congenital isolated adrenocorticotropic hormone deficiency due to pathogenic variants in TBX19
Congenital isolated ACTH deficiency (СIAD) is an orphan autosomal recessive disease caused by ТВХ19 (1q24.2) gene pathogenic variants. The article presents two cases with a classic manifestation of the СIAD in neonatal period which were confirmed genetically, one of cases revealed the first described TBX19 gene variant. Despite the appearance of significant symptoms in the newborn period in both patients diagnoses were established at the 8th and 22nd months of life. Clinical manifestations of hypoglycemia were present in both patients: from the 1st day of life (episode of apnoea) in patient № 2 and from 7 months (seizures) in patient № 1. Cholestatic jaundice, hepatomegaly, signs of hepatocyte cytolysis, impaired protein-synthetic liver function were the main manifestations of the disease in 1st patient. This may indicate non-infectious cholestatic hepatitis. Improvement and gradual normalization of clinical and laboratory symptoms during hydrocortisone therapy confirmed the association of liver damage with hypocortisolemia. 2nd patient had no signs of cholestasis. Low cortisol levels were observed with reduced or low-normal ACTH, which confirmed central hypocorticism. Genetic study in both patients revealed TBX19 gene pathogenic variants in a homozygous state: c.82C>T(p.Q28X) in patient №1, not previously described variant c.469-1G>A in patient №2.
- 22 July 2025
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 71 (3) , 51-55
Open AccessTwo cases of congenital isolated adrenocorticotropic hormone deficiency due to pathogenic variants in TBX19
Congenital isolated ACTH deficiency (СIAD) is an orphan autosomal recessive disease caused by ТВХ19 (1q24.2) gene pathogenic variants. The article presents two cases with a classic manifestation of the СIAD in neonatal period which were confirmed genetically, one of cases revealed the first described TBX19 gene variant. Despite the appearance of significant symptoms in the newborn period in both patients diagnoses were established at the 8th and 22nd months of life. Clinical manifestations of hypoglycemia were present in both patients: from the 1st day of life (episode of apnoea) in patient № 2 and from 7 months (seizures) in patient № 1. Cholestatic jaundice, hepatomegaly, signs of hepatocyte cytolysis, impaired protein-synthetic liver function were the main manifestations of the disease in 1st patient. This may indicate non-infectious cholestatic hepatitis. Improvement and gradual normalization of clinical and laboratory symptoms during hydrocortisone therapy confirmed the association of liver damage with hypocortisolemia. 2nd patient had no signs of cholestasis. Low cortisol levels were observed with reduced or low-normal ACTH, which confirmed central hypocorticism. Genetic study in both patients revealed TBX19 gene pathogenic variants in a homozygous state: c.82C>T(p.Q28X) in patient №1, not previously described variant c.469-1G>A in patient №2.
- 10 July 2025
- Published by Saint Petersburg State Pediatric Medical University of the Ministry of Health of Russia in Pediatrician (St. Petersburg)
- Vol. 16 (2) , 5-17
Кровоизлияния в надпочечники у новорожденного (проект клинических рекомендаций)
Кровоизлияние в надпочечники (КН) у новорожденного — это относительно редкое патологическое состояние (0,2 до 3,0%), возникающее в раннем неонатальном периоде, является наиболее часто встречающимся образованием надпочечников. Поражение правого надпочечника происходит чаще вследствие особенностей его анатомического расположения между печенью и позвоночником. КН в надпочечники у новорожденных может приводить к частичной или полной потере гормональной функции органа. В большинстве случаев поражение надпочечников у новорожденных развивается вторично на фоне основного заболевания, в ряде случаев причину кровоизлияния установить не удается. Наиболее частыми факторами риска являются травматичные роды, макросомия, гипоксия, артериальная гипотензия, коагулопатия, сепсис и опухоль. Ранняя диагностика КН сложна, так как клинические симптомы КН в большинстве случаев отсутствуют или не являются специфичными: интенсивная желтуха, анемия, пальпируемое болезненное образование в брюшной полости при массивном кровотечении, возможен отек и синюшное изменение цвета мошонки при разрыве капсулы надпочечника. В тяжелых случаях КН могут проявляться симптомами надпочечниковой недостаточности, гиповолемического шока и даже вероятен летальный исход. Изолированное КН у новорожденного обычно не требует медикаментозного или хирургического лечения и характеризуется регрессом симптомов в течение 12 недель или более. У новорожденных, перенесших КН, сохраняется риск развития хронической надпочечниковой недостаточности. Основным методом профилактики КН является снижение травматичности процесса родов, избрание наиболее щадящей тактики родоразрешения, исходя из особенностей каждой отдельной клинической ситуации. Adrenal hemorrhage (AH) in a newborn is a relatively rare pathological condition (0.2 to 3.0%) that occurs in the early neonatal period and is the most common adrenal formation. Damage to the right adrenal gland occurs more often due to the peculiarities of its anatomical location between the liver and the spine. Neonatal AH can lead to partial or complete loss of hormonal function of the organ. In most cases, adrenal gland damage in newborns develops secondarily against the background of the underlying disease; in some cases, the cause of hemorrhage cannot be determined. The most common risk factors are traumatic birth, macrosomia, hypoxia, arterial hypotension, coagulopathy, sepsis, and tumor. Early diagnostics of AH is difficult, since clinical symptoms of AH in most cases are absent or non-specific: intense jaundice, anemia, a palpable painful formation in the abdominal cavity with massive bleeding, possible edema and cyanotic discoloration of the scrotum with rupture of the adrenal capsule. In severe cases, AH may manifest itself with symptoms of adrenal insufficiency, hypovolemic shock, and even death is possible. Isolated AH in a newborn usually does not require medical or surgical treatment and is characterized by regression of symptoms within 12 weeks or more. Newborns who have experienced AH remain at risk of developing chronic adrenal insufficiency. The main method of preventing AH is to reduce the trauma of the birth process, choosing the most gentle tactics of delivery, based on the characteristics of each individual clinical situation.
- 10 July 2025
- Published by Saint Petersburg State Pediatric Medical University of the Ministry of Health of Russia in Pediatrician (St. Petersburg)
- Vol. 16 (2) , 5-17
Кровоизлияния в надпочечники у новорожденного (проект клинических рекомендаций)
Кровоизлияние в надпочечники (КН) у новорожденного — это относительно редкое патологическое состояние (0,2 до 3,0%), возникающее в раннем неонатальном периоде, является наиболее часто встречающимся образованием надпочечников. Поражение правого надпочечника происходит чаще вследствие особенностей его анатомического расположения между печенью и позвоночником. КН в надпочечники у новорожденных может приводить к частичной или полной потере гормональной функции органа. В большинстве случаев поражение надпочечников у новорожденных развивается вторично на фоне основного заболевания, в ряде случаев причину кровоизлияния установить не удается. Наиболее частыми факторами риска являются травматичные роды, макросомия, гипоксия, артериальная гипотензия, коагулопатия, сепсис и опухоль. Ранняя диагностика КН сложна, так как клинические симптомы КН в большинстве случаев отсутствуют или не являются специфичными: интенсивная желтуха, анемия, пальпируемое болезненное образование в брюшной полости при массивном кровотечении, возможен отек и синюшное изменение цвета мошонки при разрыве капсулы надпочечника. В тяжелых случаях КН могут проявляться симптомами надпочечниковой недостаточности, гиповолемического шока и даже вероятен летальный исход. Изолированное КН у новорожденного обычно не требует медикаментозного или хирургического лечения и характеризуется регрессом симптомов в течение 12 недель или более. У новорожденных, перенесших КН, сохраняется риск развития хронической надпочечниковой недостаточности. Основным методом профилактики КН является снижение травматичности процесса родов, избрание наиболее щадящей тактики родоразрешения, исходя из особенностей каждой отдельной клинической ситуации. Adrenal hemorrhage (AH) in a newborn is a relatively rare pathological condition (0.2 to 3.0%) that occurs in the early neonatal period and is the most common adrenal formation. Damage to the right adrenal gland occurs more often due to the peculiarities of its anatomical location between the liver and the spine. Neonatal AH can lead to partial or complete loss of hormonal function of the organ. In most cases, adrenal gland damage in newborns develops secondarily against the background of the underlying disease; in some cases, the cause of hemorrhage cannot be determined. The most common risk factors are traumatic birth, macrosomia, hypoxia, arterial hypotension, coagulopathy, sepsis, and tumor. Early diagnostics of AH is difficult, since clinical symptoms of AH in most cases are absent or non-specific: intense jaundice, anemia, a palpable painful formation in the abdominal cavity with massive bleeding, possible edema and cyanotic discoloration of the scrotum with rupture of the adrenal capsule. In severe cases, AH may manifest itself with symptoms of adrenal insufficiency, hypovolemic shock, and even death is possible. Isolated AH in a newborn usually does not require medical or surgical treatment and is characterized by regression of symptoms within 12 weeks or more. Newborns who have experienced AH remain at risk of developing chronic adrenal insufficiency. The main method of preventing AH is to reduce the trauma of the birth process, choosing the most gentle tactics of delivery, based on the characteristics of each individual clinical situation.
- 30 December 2024
- Published by Saint Petersburg State Pediatric Medical University of the Ministry of Health of Russia in Pediatrician (St. Petersburg)
- Vol. 15 (4) , 125-133
One hundred years of endocrinology in Russia. From the history of pediatric endocrinology in Saint Petersburg
Endocrinology, one of the most dynamically developing branches of medicine, has existed as a separate discipline for a little over 100 years. The author of one of the first guidelines on endocrinology in Russia and the founder of the Leningrad School of Clinical Endocrinology was Professor Vasily G. Baranov (1899–1988). In 1926, an endocrinology department was opened at the Department of Therapy of the Leningrad State Institute for Advanced Medical Training under the leadership of Vasily Gavrilovich. Later, in 1963, Professor V.G. Baranov founded the Department of Endocrinology at this educational institution, which currently bears the name of the scientist. V.G. Baranov paid special attention to the issues of endocrine diseases in childhood. Together with academician A.F. Tur, he initiated the creation of an endocrinological service in pediatrics. It was only in 1998 that a new specialty “pediatric endocrinology” was added to the already existing training programs for doctors in the specialty “endocrinology”, opened by order of the Ministry of Health of the Russian Federation. However, the development and formation of pediatric endocrinology as a separate medical discipline took place before official recognition. A special role in the history of this formation belongs to the doctors of St. Petersburg.
- 30 December 2024
- Published by Saint Petersburg State Pediatric Medical University of the Ministry of Health of Russia in Pediatrician (St. Petersburg)
- Vol. 15 (4) , 125-133
One hundred years of endocrinology in Russia. From the history of pediatric endocrinology in Saint Petersburg
Endocrinology, one of the most dynamically developing branches of medicine, has existed as a separate discipline for a little over 100 years. The author of one of the first guidelines on endocrinology in Russia and the founder of the Leningrad School of Clinical Endocrinology was Professor Vasily G. Baranov (1899–1988). In 1926, an endocrinology department was opened at the Department of Therapy of the Leningrad State Institute for Advanced Medical Training under the leadership of Vasily Gavrilovich. Later, in 1963, Professor V.G. Baranov founded the Department of Endocrinology at this educational institution, which currently bears the name of the scientist. V.G. Baranov paid special attention to the issues of endocrine diseases in childhood. Together with academician A.F. Tur, he initiated the creation of an endocrinological service in pediatrics. It was only in 1998 that a new specialty “pediatric endocrinology” was added to the already existing training programs for doctors in the specialty “endocrinology”, opened by order of the Ministry of Health of the Russian Federation. However, the development and formation of pediatric endocrinology as a separate medical discipline took place before official recognition. A special role in the history of this formation belongs to the doctors of St. Petersburg.
- Open Access
- 9 March 2024
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 70 (6) , 106-117
A new way for the differential diagnosis of hypogonadotropic hypogonadism and constitutional delay of puberty in adolescent men aged 13.5–17 years
BACKGROUND: Differential diagnosis of hypogonadotropic hypogonadism (HH) and constitutional delay of puberty (CDP) is extremely important since with the latter puberty begins and completes without any medical intervention and in the case of HH puberty does not occur or is incomplete. Failure to start treatment on time leads to medical and psychosocial maladjustment of the patient.AIM: Development of a method for differential diagnosis of hypogonadotropic hypogonadism and constitutional delay of puberty in boys 13.5–17 years old by scoring the levels of LH, FSH, testosterone and inhibin B.MATERIALS AND METHODS: The study group was formed by adolescent men 13.5–17 years old with delayed puberty including all observations. Anamnesis, stage of puberty, testicular volume were assessed; serum levels of LH, FSH, testosterone (T) were determined by chemiluminescent analysis and inhibin B, AMH by ELISA. Stimulation tests were performed with triptorelin and human chorionic gonadotropin (3 days). Patients were followed up for 6–24 months.RESULTS: The study included adolescent men at the age of 13.5–17 years with delayed puberty: 56 for the purpose of development a method of differential diagnosis, 30 for its control (control group). We`ve created a method that allows differentiate HH and CDP. Through the ROC-analysis the most sensitive and specific HH markers were identified. The basal levels of LH, FSH, T, and inhibin B were selected as most available for outpatient testing. Based on the results of our own research and scientific data we selected ranges of values and rated LH, FSH, T and inhibin B depending on them (marks). Then we assigned the coefficients (k) for each hormone. Scores were calculated by multiplying the marks by k then summed and normalized to the maximum amount the patient could get. To increase the accuracy of diagnosis an age coefficient was introduced. The result of the calculation was the result of the scoring (S). S for CDP (10.65 [3.13–14.91]) differed significantly from that for HH (76.46 [57.79–83.74]) (p< 0.001). Diagnoses based on S (CONCLUSION: The result of scoring of LH, FSH, testosterone, inhibin B levels ≥55.07 makes it possible to diagnose hypogonadotropic hypogonadism, < 21.16 — constitutional delay of puberty with a high probability. In the case of score ≥21.16 but < 55.07, calculation of the inhibin B/AMH ratio and/or stimulation tests are required.
- 9 March 2024
- Published by Endocrinology Research Centre in Problems of Endocrinology
- Vol. 70 (6) , 106-117
Open AccessA new way for the differential diagnosis of hypogonadotropic hypogonadism and constitutional delay of puberty in adolescent men aged 13.5–17 years
BACKGROUND: Differential diagnosis of hypogonadotropic hypogonadism (HH) and constitutional delay of puberty (CDP) is extremely important since with the latter puberty begins and completes without any medical intervention and in the case of HH puberty does not occur or is incomplete. Failure to start treatment on time leads to medical and psychosocial maladjustment of the patient.AIM: Development of a method for differential diagnosis of hypogonadotropic hypogonadism and constitutional delay of puberty in boys 13.5–17 years old by scoring the levels of LH, FSH, testosterone and inhibin B.MATERIALS AND METHODS: The study group was formed by adolescent men 13.5–17 years old with delayed puberty including all observations. Anamnesis, stage of puberty, testicular volume were assessed; serum levels of LH, FSH, testosterone (T) were determined by chemiluminescent analysis and inhibin B, AMH by ELISA. Stimulation tests were performed with triptorelin and human chorionic gonadotropin (3 days). Patients were followed up for 6–24 months.RESULTS: The study included adolescent men at the age of 13.5–17 years with delayed puberty: 56 for the purpose of development a method of differential diagnosis, 30 for its control (control group). We`ve created a method that allows differentiate HH and CDP. Through the ROC-analysis the most sensitive and specific HH markers were identified. The basal levels of LH, FSH, T, and inhibin B were selected as most available for outpatient testing. Based on the results of our own research and scientific data we selected ranges of values and rated LH, FSH, T and inhibin B depending on them (marks). Then we assigned the coefficients (k) for each hormone. Scores were calculated by multiplying the marks by k then summed and normalized to the maximum amount the patient could get. To increase the accuracy of diagnosis an age coefficient was introduced. The result of the calculation was the result of the scoring (S). S for CDP (10.65 [3.13–14.91]) differed significantly from that for HH (76.46 [57.79–83.74]) (p< 0.001). Diagnoses based on S (CONCLUSION: The result of scoring of LH, FSH, testosterone, inhibin B levels ≥55.07 makes it possible to diagnose hypogonadotropic hypogonadism, < 21.16 — constitutional delay of puberty with a high probability. In the case of score ≥21.16 but < 55.07, calculation of the inhibin B/AMH ratio and/or stimulation tests are required.
- Open Access
- 12 August 2022
- Published by Saint Petersburg State Pediatric Medical University of the Ministry of Health of Russia in Pediatrician (St. Petersburg)
- Vol. 13 (3) , 15-22
The use of stimulation tests for the differential diagnosis of delayed puberty in boys. How to increase the specificity of the method?
BACKGROUND: In patients with a constitutional delay of puberty starts and ends completely without any medical intervention. In adolescents with hypogonadotropic hypogonadism puberty is absent or does not continue its development. Differential diagnosis of the conditions is complicated due to lack of standard recommendations for the selection, conducting and assessment of stimulation tests. AIM: To assess the information content and find ways to increase the specificity of stimulation tests with triptorelin and corionic gonadotropin in relation to hypogonadotropic hypogonadism. MATERIALS AND METHODS: We examined 44 adolescent boys aged 13.517 years with delayed puberty. Sexual development was assessed according to Tanner scale, bone age (X-ray of the non-dominant hand according to the Greulich atlas). All boys were tested with triptorelin. The test with one- and three-day intramuscular injection of human chorionic gonadotropin was performed in 26 and 35 patients, respectively. Statistical analysis was performed using the StatTech v. 2.6.1 (developer Stattech LLC, Russia). To assess the diagnostic significance of quantitative signs in predicting a certain outcome the ROC-curve analysis was performed. RESULTS: It was revealed that a negative test with triptorelin was observed in some patients with constitutional delay of puberty. Threshold stimulated luteinizing hormone and follicle stimulating hormone levels were set (8.90 and 5.90 IU/l respectively). Gonadotropins values equal to or lower than selected thresholds allow diagnosing of hypogonadotropic hypogonadism with high sensitivity and specificity. Threshold testosterone levels stimulated by one- and three-day administration of human chorionic gonadotropin were determined (2.11 and 5.84 nmol/l respectively). Testosterone values equal to or lower than selected thresholds allow diagnosing of hypogonadotropic hypogonadism with high sensitivity and specificity. A high degree of positive correlation was found between stimulated luteinizing hormone levels and stimulated testosterone levels during a three-day test with human chorionic gonadotropin. CONCLUSIONS: A negative test with triptorelin is observed in some patients with constitutional delay of puberty. The specificity of the test can be improved by using threshold stimulated levels of luteinizing hormone and follicle stimulating hormone (8.90 and 5.90 IU/L, respectively). The use of the threshold levels of testosterone (2.11 and 5.84 nmol/l within the one- and three-day functional tests of the testicles respectively) can help to increase the specificity of the considered outdated stimulation tests with human chorionic gonadotropin.
- 12 August 2022
- Published by Saint Petersburg State Pediatric Medical University of the Ministry of Health of Russia in Pediatrician (St. Petersburg)
- Vol. 13 (3) , 15-22
Open AccessThe use of stimulation tests for the differential diagnosis of delayed puberty in boys. How to increase the specificity of the method?
BACKGROUND: In patients with a constitutional delay of puberty starts and ends completely without any medical intervention. In adolescents with hypogonadotropic hypogonadism puberty is absent or does not continue its development. Differential diagnosis of the conditions is complicated due to lack of standard recommendations for the selection, conducting and assessment of stimulation tests. AIM: To assess the information content and find ways to increase the specificity of stimulation tests with triptorelin and corionic gonadotropin in relation to hypogonadotropic hypogonadism. MATERIALS AND METHODS: We examined 44 adolescent boys aged 13.517 years with delayed puberty. Sexual development was assessed according to Tanner scale, bone age (X-ray of the non-dominant hand according to the Greulich atlas). All boys were tested with triptorelin. The test with one- and three-day intramuscular injection of human chorionic gonadotropin was performed in 26 and 35 patients, respectively. Statistical analysis was performed using the StatTech v. 2.6.1 (developer Stattech LLC, Russia). To assess the diagnostic significance of quantitative signs in predicting a certain outcome the ROC-curve analysis was performed. RESULTS: It was revealed that a negative test with triptorelin was observed in some patients with constitutional delay of puberty. Threshold stimulated luteinizing hormone and follicle stimulating hormone levels were set (8.90 and 5.90 IU/l respectively). Gonadotropins values equal to or lower than selected thresholds allow diagnosing of hypogonadotropic hypogonadism with high sensitivity and specificity. Threshold testosterone levels stimulated by one- and three-day administration of human chorionic gonadotropin were determined (2.11 and 5.84 nmol/l respectively). Testosterone values equal to or lower than selected thresholds allow diagnosing of hypogonadotropic hypogonadism with high sensitivity and specificity. A high degree of positive correlation was found between stimulated luteinizing hormone levels and stimulated testosterone levels during a three-day test with human chorionic gonadotropin. CONCLUSIONS: A negative test with triptorelin is observed in some patients with constitutional delay of puberty. The specificity of the test can be improved by using threshold stimulated levels of luteinizing hormone and follicle stimulating hormone (8.90 and 5.90 IU/L, respectively). The use of the threshold levels of testosterone (2.11 and 5.84 nmol/l within the one- and three-day functional tests of the testicles respectively) can help to increase the specificity of the considered outdated stimulation tests with human chorionic gonadotropin.